Condyloma Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Prescription Drugs and Surgeries), By End User (Hospitals, Retail Pharmacies, and Online Pharmacies),and Region Forecast 2024-2030

Condyloma Market size was valued at US$ 1,739.7 million in 2023 and is poised to grow at a significant CAGR of 5.1% from 2024-2030. Anogenital warts spurred on by the human papillomavirus (HPV) are referred to as condyloma acuminate and can affect both the male and female populations. Anogenital warts are most frequently carried on by HPV strains 6 and 11. Warts can develop anywhere near the vagina, cervix (in females), and scrotum, penis, groin, or thighs (in males). A double-stranded DNA virus called HPV is typically transmitted through intercourse.

Condyloma acuminata susceptibility is influenced by one's age, way of life, and sexual habits. Topical treatments include imiquimod cream, sinecatechins ointment, and solutions and creams containing podophyllotoxin. Other viable therapies include cryotherapy, trichloroacetic acid solution, and several surgical techniques. Following topical therapies, Condyloma acuminata has a possibility of returning. The only therapy with clearance rates close to 100% is surgical excision. Patients should be advised on available treatments, the value of follow-up visits, and safe sex procedures. With 9 to 13 percent of the world's population afflicted, HPV is the most prevalent sexually transmitted illness.

Most often, patients between the ages of 20 and 39 are impacted. Thus, with high prevalence, primarily in the young generation, the condyloma treatment market is predicted to grow in the presumption period. There are several identified risk factors for HPV infection.The likelihood of contracting an infection rises with more past sexual partners, a history of gonorrhea and chlamydia infections, smoking, and HIV infection. With around 10 million cigarettes sold worldwide and 36.9 million people living with HIV (including 1.8 million children), the chances of condyloma morbidity are to increase in the future, thus giving the thrust for the market growth. The occurrence of condyloma acuminata is challenging to predict since anogenital warts are not a disease that must be reported.

However, according to current estimates, there are 1.1 to 1.2 incidences of anogenital warts per 1000 people per year in the United States. Further, there are international level efforts by the World Health Organization to educate the population through an authoritarian level awareness campaign and eliminate sexually transmitted diseases by providing health care facilities and funds to the governments worldwide, which will drive the condyloma treatment market to flourish in the prognosticate span of the report. The major restrain for the market is the nonreporting of the disease. The disease prevalence is much higher than reported as this disease is typically nonlethal many infected patients never report it.

Key Developments

• March 2021, Verrica signed a License Agreement with Torii Pharmaceutical Co. Ltd. granting Torii an exclusive license to develop and commercialize Verricas product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
• In October 2018, Novan entered partnership with Health Decisions, a specialist Contract Research Organization (CRO), and announced clinical trial Phase II data for the treatment of external genital warts (EGW).